Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30318506)

  • 1. An IL13Rα2 peptide exhibits therapeutic activity against metastatic colorectal cancer.
    Bartolomé RA; Jaén M; Casal JI
    Br J Cancer; 2018 Oct; 119(8):940-949. PubMed ID: 30318506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
    Nguyen V; Conyers JM; Zhu D; Gibo DM; Hantgan RR; Larson SM; Debinski W; Mintz A
    Neuro Oncol; 2012 Oct; 14(10):1239-53. PubMed ID: 22952195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.
    Kim K; Gwak HS; Han N; Hong EK; Choi BK; Lee S; Choi S; Park JH; Seok JH; Jeon Y; Cho H; Lee SJ; Lee Y; Nam KT; Song SW
    Front Immunol; 2021; 12():715000. PubMed ID: 34819930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel target anti-interleukin-13 receptor subunit alpha-2 monoclonal antibody inhibits tumor growth and metastasis in lung cancer.
    Raza G; Yunus FU; Mangukiya HB; Merugu SB; Mashausi DS; Zeling W; Negi H; Zhou B; Roy D; Wu Z; Li D
    Int Immunopharmacol; 2021 Jan; 90():107155. PubMed ID: 33243603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential expression of the alpha2 chain of the interleukin-13 receptor in metastatic human prostate cancer ARCaPM cells.
    He H; Xu J; Nelson PS; Marshall FF; Chung LW; Zhau HE; He D; Wang R
    Prostate; 2010 Jun; 70(9):993-1001. PubMed ID: 20166133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-13 receptor α2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice.
    Xie M; Wu XJ; Zhang JJ; He CS
    Oncotarget; 2015 Oct; 6(32):32902-13. PubMed ID: 26418721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 13 receptor alpha 2 (IL13Rα2): Expression, signaling pathways and therapeutic applications in cancer.
    Jaén M; Martín-Regalado Á; Bartolomé RA; Robles J; Casal JI
    Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188802. PubMed ID: 36152905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
    Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
    Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Liver Metastasis in Colorectal Cancer by Targeting IL-13/IL13Rα2 Binding Site with Specific Monoclonal Antibodies.
    Jaén M; Bartolomé RA; Aizpurua C; Martin-Regalado Á; Imbaud JI; Casal JI
    Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33917458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis.
    Papageorgis P; Ozturk S; Lambert AW; Neophytou CM; Tzatsos A; Wong CK; Thiagalingam S; Constantinou AI
    Breast Cancer Res; 2015 Jul; 17(1):98. PubMed ID: 26208975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
    Hegde M; Mukherjee M; Grada Z; Pignata A; Landi D; Navai SA; Wakefield A; Fousek K; Bielamowicz K; Chow KK; Brawley VS; Byrd TT; Krebs S; Gottschalk S; Wels WS; Baker ML; Dotti G; Mamonkin M; Brenner MK; Orange JS; Ahmed N
    J Clin Invest; 2016 Aug; 126(8):3036-52. PubMed ID: 27427982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
    Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
    Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL13 Receptor α2 Signaling Requires a Scaffold Protein, FAM120A, to Activate the FAK and PI3K Pathways in Colon Cancer Metastasis.
    Bartolomé RA; García-Palmero I; Torres S; López-Lucendo M; Balyasnikova IV; Casal JI
    Cancer Res; 2015 Jun; 75(12):2434-44. PubMed ID: 25896327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2.
    Balyasnikova IV; Wainwright DA; Solomaha E; Lee G; Han Y; Thaci B; Lesniak MS
    J Biol Chem; 2012 Aug; 287(36):30215-27. PubMed ID: 22778273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression.
    Kwiatkowska A; Kijewska M; Lipko M; Hibner U; Kaminska B
    Biochim Biophys Acta; 2011 May; 1813(5):655-67. PubMed ID: 21276823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel interleukin-13 receptor alpha 2-targeted hybrid peptide for effective glioblastoma therapy.
    Kurihara R; Horibe T; Shimizu E; Torisawa A; Gaowa A; Kohno M; Kawakami K
    Chem Biol Drug Des; 2019 Jul; 94(1):1402-1413. PubMed ID: 30903640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An MSN-PEG-IP drug delivery system and IL13Rα2 as targeted therapy for glioma.
    Shi J; Hou S; Huang J; Wang S; Huan W; Huang C; Liu X; Jiang R; Qian W; Lu J; Wang X; Shi W; Huang R; Chen J
    Nanoscale; 2017 Jul; 9(26):8970-8981. PubMed ID: 28443896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
    Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
    Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy.
    Gu A; Bai Y; Zhang C; Xu C; An Z; Zhang Y; Zhong SH; Hu Y; Zhong X
    Cancer Immunol Immunother; 2023 Jul; 72(7):2393-2403. PubMed ID: 36991262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.